Nanocelle® Nasal Spray: Formulation Development and Biological Characterisation of Insulin Nanomicelle

Chun Yuen Jerry Wong1, Tomas Andersen2, Michelle Quezada2, Julie Suman3, Luis Vitetta2,4, Hui Xin Ong1,5 & Daniela Traini1,5

1Woolcock Institute of Medical Research, Sydney, NSW, 2037, Australia

2Research Department, Medlab Clinical, Sydney, NSW, 2015, Australia

3Aptar Pharma, Congers, 10920, NY, United States

4Faculty of Medicine and Health, University of Sydney, Sydney, Australia

5Faculty of Medicine and Health Sciences, Macquarie Medical School, Macquarie University, Sydney, Australia


The present study developed an insulin nano-sized drug delivery system to be delivered to the nasal cavity using a proprietary carrier technology (Nanocelle®, MedLab). The main objective was to evaluate the physicochemical properties and permeation efficacy of the insulin Nanocelle on RPMI-2650 human nasal epithelial cells. The stability of the developed formulation was analysed in terms of particle size, polydispersity index and zeta potential. The use of Nanocelle to encapsulate insulin did not elicit any toxicity in RPMI-2650 nasal cells. Nanocelle allowed direct drug permeation through the nasal epithelial cells, with approximately 44.93 ± 3.33 % of drug permeated in the first 0.5 hours. This preliminary study demonstrated how insulin Nanocelle could be used therapeutically to deliver proteins via the intranasal route as a non-invasive prophylactic strategy for cognitive deficits and blood glucose control.

Key Message

This study showed that Nanocelle® at pH 4.8 possesses great potential for nasal delivery of insulin. The nanoformulation demonstrated promising physicochemical properties and stability. Its potential in facilitating insulin translocation was supported by negligible cytotoxicity and no noticeable effect on the tight junction on the RPMI-2650 nasal cell model.